EP4704882A2 - Behandlung von muskelschwäche mit alkalischen phosphatasen - Google Patents

Behandlung von muskelschwäche mit alkalischen phosphatasen

Info

Publication number
EP4704882A2
EP4704882A2 EP24800338.6A EP24800338A EP4704882A2 EP 4704882 A2 EP4704882 A2 EP 4704882A2 EP 24800338 A EP24800338 A EP 24800338A EP 4704882 A2 EP4704882 A2 EP 4704882A2
Authority
EP
European Patent Office
Prior art keywords
subject
recombinant polypeptide
administration
years
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24800338.6A
Other languages
English (en)
French (fr)
Inventor
Denise DEVORE
Anna PETRYK
Walter VOEGTLI
Derek Dunn
Juan RUANOVA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of EP4704882A2 publication Critical patent/EP4704882A2/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24800338.6A 2023-05-02 2024-03-26 Behandlung von muskelschwäche mit alkalischen phosphatasen Pending EP4704882A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363463539P 2023-05-02 2023-05-02
PCT/US2024/021544 WO2024228791A2 (en) 2023-05-02 2024-03-26 Treating muscle weakness with alkaline phosphatases

Publications (1)

Publication Number Publication Date
EP4704882A2 true EP4704882A2 (de) 2026-03-11

Family

ID=93333251

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24800338.6A Pending EP4704882A2 (de) 2023-05-02 2024-03-26 Behandlung von muskelschwäche mit alkalischen phosphatasen

Country Status (7)

Country Link
EP (1) EP4704882A2 (de)
KR (1) KR20260005379A (de)
CN (1) CN121038804A (de)
AU (1) AU2024265262A1 (de)
CO (1) CO2025016761A2 (de)
MX (1) MX2025013039A (de)
WO (1) WO2024228791A2 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7613826B2 (ja) * 2016-04-01 2025-01-15 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼによって筋力低下を治療すること
CA3161266A1 (en) * 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US20240207370A1 (en) * 2021-04-26 2024-06-27 University Of Massachusetts Gene therapy for bcaa modulation in maple syrup urine disease (msud)

Also Published As

Publication number Publication date
WO2024228791A3 (en) 2025-01-09
WO2024228791A2 (en) 2024-11-07
KR20260005379A (ko) 2026-01-09
CO2025016761A2 (es) 2026-04-27
WO2024228791A9 (en) 2025-02-27
AU2024265262A1 (en) 2025-12-11
CN121038804A (zh) 2025-11-28
MX2025013039A (es) 2025-12-01

Similar Documents

Publication Publication Date Title
US11186832B2 (en) Treating muscle weakness with alkaline phosphatases
US11065306B2 (en) Methods for treating hypophosphatasia in children
US20230201318A1 (en) Methods for treating hypophosphatasia in children and adolescents
AU2018243320B2 (en) Methods for treating hypophosphatasia (HPP) in adults and adolescents
US20200121767A1 (en) Methods for identifying the health state of hypophosphatasia (hpp) patients
JP2023540741A (ja) 骨石灰化障害を処置する方法
EP4704882A2 (de) Behandlung von muskelschwäche mit alkalischen phosphatasen
US20260041742A1 (en) Method and compositions for treatment, amelioration, and/or prevention of diffuse idiopathic skeletal hyperostosis (dish)
BR112024019927B1 (pt) Uso de um composto para melhorar e/ou prevenir a hiperostose esquelética idiopática difusa (dish
RU2774620C2 (ru) Способы лечения гипофосфатазии (гфф) у взрослых и подростков
CN116710122A (zh) Enpp1缺乏症和abcc6缺乏症的治疗
CN121816188A (zh) 儿童enpp1缺乏症和abcc6缺乏症的治疗

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR